Compare Adaptive Biotechnologies Corp (ADPT) vs Moody's Corporation (MCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Moody's Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Moody's Corporation trades at $487.58 (market cap $87.42B). The key difference: Moody's Corporation is far larger — about 26.3× Adaptive Biotechnologies Corp's market cap, and Moody's Corporation pays a 0.82% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MCO | |
|---|---|---|
Market Cap | $3.33B | $87.42B |
Sector | Health | Financials |
52-Week High | $22.37 | $539.61 |
52-Week Low | $10.24 | $412.23 |
Enterprise Value | $3.19B | $93.23B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Moody's Corporation (MCO) trades at $500.49, up 2.03% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 31.69% net margins and consistent earnings beats, while trading at premium valuations (P/E 35.78). Recent AI integration announcements and dividend payments highlight strategic growth initiatives.
MCO presents a compelling growth story with strong profitability and analyst support (56% buy ratings, $542 consensus target), though elevated valuations and RSI overbought signals warrant caution. Key risks include competitive pressures and market sensitivity to credit cycles, but the company's market position and AI strategy support long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
